1. Introduction {#sec2}
===============

Non alcoholic fatty liver disease (NAFLD) has the prevalence of 15%--20%. It is the amassing of fats in the hepatic tissue without significant alcohol intake that result in hepatic steatosis [@bib1]. NAFLD includes a broad range of liver conditions including plain fattiness in hepatic tissue which is static to progressive steatohepatitis that may progress to cirrhotic changes and hepatic carcinoma [@bib2], [@bib3], [@bib4]. NAFLD contributes as the commonest cause that leads to cirrhosis and approximately 22% of NAFLD progresses to cirrhosis as reported by studies. Currently there is no medical remedy to stop this progression or to reverse the cirrhotic condition. How ever weight reduction is the mainstay of preventing cirrhosis in NAFLD patients [@bib5]. Non alcoholic fatty liver disease happens in two phases. First triglycerides get accumulates in liver without hepatic damage and later on hepatic damage takes place. Lipid peroxidation and oxidative stress are the understood noxious pathologies [@bib6], [@bib7].

Patients with gallstones have associated NAFLD, with concurrent metabolic syndrome and these ailments share similar factors for example obesity, hypertriglyceridemia and diabetes mellitus [@bib8].

Gallstone forms by the precipitation of calcium, bilirubin, cholesterol mucous and proteins. It is one of the commonest ailments presenting to surgical units. A study reported an incidence of 9.03% [@bib9]. Nearly 75% of the patients with gall stones are symptomless [@bib10].

Factors like body mass index, gender, raised lipid levels, use of contraceptives and alcohol and having diabetes [@bib11], [@bib12], physical inactiveness [@bib13], multiparous women [@bib14], water with excessive iron content [@bib15], metabolic syndrome [@bib16], and NAFLD [@bib1] are accountable factors for gallstones formation.

The presence of three or more of the following five factors is defined as the Metabolic Syndrome by Adult Treatment Panel III (ATP III) criteria. [@bib17], [@bib18]: (1) hypertriglyceridemia: (higher TG) greater than 150 mg/dL; (2)abdominal obesities e waist girth in men greater than 90 cm and in women greater than 80 cm (3) lower HDL-C: serum HDL-C less than 40 mg/dL in men and \<50 mg/dL in women; (4)hyperglycemia: fasting plasma glucose greater than 100 mg/dL or DM history (including medical record or self-reported). (5) elevated blood pressure (systolic blood pressure greater than 130 mmHg or diastolic blood pressure greater than 85 mmHg or hypertension history (including medical record or self-reported).

The study will be a paradigm to identify the presence of Non alcoholic fatty liver disease (NAFLD) and metabolic syndrome in patients with gallstones undergoing laparoscopic or open cholecystectomy along with it we will also study the life style of patients with gall stones. Also role of metabolic syndrome in pathophysiology of Non alcoholic fatty liver disease and gallstone will be identified as well as their interrelation.

2. Objective {#sec3}
============

Recognition of Non alcoholic fatty liver disease (NAFLD) and metabolic syndrome in patients with gallstones undergoing laparoscopic or open cholecystectomy, along with it we will also study the life style of patients with gall stones.

3. Methodology {#sec4}
==============

This was a case series done at Surgical Unit 1 of Civil Hospital Karachi. Selective samples of 88 patients were included in this which was calculated by [www.OpenEpi.com](http://www.OpenEpi.com){#interref0010} taking the population size of 95 at 95% CI and 3% margin of error [@bib19]. Duration was 3 months. Institutional review board approval for research proposal was also taken from Dow University Of Health Sciences with reference id of IRB-748/DUHS/Approval/2016/240. Random sampling was done. We included both sexes with ultrasound proof of gall stone irrespective of cholecystitis. Excluded patients with history of seropositive viral hepatitis, autoimmune and wilson\'s disease. As these conditions can act as a confounder to our variables. After signing a consent all the relevant data was collected on a proforma. To make the liver ultrasound report more authentic and to pick up NAFLD more critically a well experience sonographer was given the duty to see the participants of our research. All data collected data was entered and analyzed via SPSS-20.

4. Results {#sec5}
==========

Analysis of the data showed 37.5% (n = 33) were males and 62.5%(n = 55) were females. The mean age of the participants was 36.40 ± 12.97. Majority were married (78.4%). 37.5% belonged to the rural areas while 62.5% were from urban areas. A huge percentage (45.5%) had history of addiction Beatle nut chewing was reported by 40.5% and smoking in 5%. 39% drink un-boiled water. 38.77% reported taking oral contraceptive pills. About 38.6% had abdominal surgery in the past.

[Table 1](#tbl1){ref-type="table"} is representing the education statuses our participant which is showing a very less literacy rate. Most of our participants had no exercise habit as shown by [Table 2](#tbl2){ref-type="table"}.

26.94% had BMI less than 18, 32.12 had BMI between 18 and 25 and majority had BMI greater than 25 i.e in 40.93%. The mean weight was 65.7 and standard deviation of ± 15.6 the mean height was 1.6 m and standard deviation of 0.109 m. Abdominal circumference came out to be 87.5 ± 5.8.

Of all 46.6% had a family history of cholelithiasis. Gallstone patients with NAFLD reported about their first degree relative being suffering from cholelithiasis at a significant p-value of 0.034 while this was not significant in cases of metabolic syndrome and the p -value was 0.190.

As far as the parity is concerned 90.73% were multipara. Systolic BP was greater than 130 in 55.30% and diasystolic BP was greater than 85 in 56.69%.

Nafld was present in 62.5% (n = 55) while 28.4% (n = 25) had metabolic syndrome.

The patients with metabolic syndrome had a co morbid of hypertension and diabetes at a p-values of 0.001. and 0.00, respectively which were highly significant.

The patient with NAFLD had hypertension and diabetes as a co morbid at a p-values of 0.89 and 0.336, respectively. There is no gender related association of metabolic syndrome nor NAFLD as shown by [Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}.

Patients with the presence of metabolic syndrome had higher mean SGPT level i.e 86.96 as compared to patients with absent metabolic syndrome (48.09) at a p-value of 0.005. The triglyceride levels in patients with presence metabolic syndrome was higher(mean = 162.5200) and the p value was 0.00 and HDL was significantly low(mean = 98.3600) at a p value of 0.001([Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}).

Patients with presence of nafld were found to have deranged SGPT and SGOT(Means = 74.4182 and 75.7273) as compared to the ones with absent of nafld at a p value of 0.002 and 0.006 respectively. ([Table 5](#tbl5){ref-type="table"}, [Table 6](#tbl6){ref-type="table"}).

5. Discussion {#sec6}
=============

A nation wide survey conducted in America revealed a very high prevalence of cholelithiasis i.e. 13.9%--26.7% in women and 5.3%--8.9% in men under the domain of third National Health and Nutrition Examination Survey [@bib20]. In Pakistan, the prevalence of gallstone is still not known. However in India which is the neighbouring country to Pakistan with similar geography and ethnicity had a study on 5100 and 1448 people with and without symptoms of gallstones. They had gallbladder ultrasonography that showed noteworthy figures of prevalence of 5.59% in women and 1.99% in males [@bib21]. Our study showed this trend as well, as most (62.5%) of the gallstone patients were females. There is a general conjecture that sex hormones and cholesterol metabolism have possible interrelation [@bib16]. This makes a point to ruminate on how sex is implicated in cholesterol stones formation. Most of the studies suggest female predominance when it comes to the prevalence of gallstones along with it the likelihood of being at risk for stone formation [@bib20], [@bib21], [@bib22]. On contrary, Liu CM et al. denied gender relation to gallstones [@bib23]. . The mean age of the participants was 36.40 ± 12.97 and this was in line with the results of study by Lirussi F. et al. that indicated an existence of high age relation with cholelithiasis more astounded in women [@bib22]. Liu CM et al. explained since people with high age had been more exposed to a pile of chronic factors like alcohol intake, hyperlipidemia and diabetes mellitus (DM), hence they are more prone to gallstone development due to manifestation of decreased motility of gallbladder [@bib23].

Chen LY et al. [@bib16] while discussing gallstone formation phenomenon also favored the theory of hyperlipidemia, decreased motility of gall bladder being overweight and insulin resistance as culprit factors of cholelithiasis pathology. According to him separation of crystals of cholesterol from supersaturated bile is the prime event. Phospholipids and bile acids makes cholesterol more soluble and prevents its precipitation. Phospholipid transfer protein (PLTP) transfers lipids from low-density lipoproteins to high-density lipoproteins. In hyperlipidemia, haptoglobin inhibits PLTP and results in reversal of cholesterol transport. Cholesterol transporter ABCG5-G8 and phospholipid floppase ABCB4 polymorphisms makes one vulnerable to gallstone risk [@bib16]. Protein kinase(PKCβ)is also considered as a major physiological regulator of lipids [@bib16].

A huge percentage (45.5%) of our participants had habit of addiction. Of all 5% had smoking addiction. Diehl et al. [@bib24] argued about role of smoking in stone formation as nicotine would probably raises the lithogeneity of the bile. Beatle nut chewing was very commonly seen in our study and 40.5% had its addiction which is much higher than another study which reported a figure of 16.6% in the neighbouring country India [@bib25].

None of our study participant had alcoholism habit. Alcohol consumption counts as a contributing factor for gallstone formation [@bib11], [@bib12]. In oppose to this there is a study that says that intake of small to moderate amount of alcohol lowers the biliary cholesterol saturation index and thus act as protective [@bib26].

In this study 39% used to drink un-boiled water. Unisa S et al. also noticed the drinking of water from unsafe source was common in gallstone patients [@bib21]. 38.77% reported taking oral contraceptive pills which is a known risk factor for cholelithiasis [@bib11], [@bib12].

Our study results were also in coherence with another series in matter of educational status as most of the participants were found to have low education [@bib21]. As per [Table 2](#tbl2){ref-type="table"} most of the study participants had inactive lifestyle. Physical inactiveness is a well known factor accounted for gallstones [@bib13].

About 38.6% had abdominal surgery in the past. A with retrospective study design showed that major abdominal surgery can result in acceleration of stone formation. However this needs to be confirmed through a prospective research so that prophylactic measures could be taken [@bib27].

Majority (40.93%) of our participants had a BMI greater than 25([Fig. 1](#fig1){ref-type="fig"}), nevertheless the mean of abdominal circumference came out to be greater as well i.e. 87.5 ± 5.8. Our results in terms of BMI are quite different from another study that reported 80% of patients had normal BMI and that was no different than control group [@bib25]. Obese women are slightly higher risk of stone formation as compared to women with ideal BMI especially when talking about cholesterol gallstone [@bib24]. The observation of Trotman has brought the fact into light that pigment GS and with cholesterol GS patients had no differences in their BMIs [@bib28].

Our results show 46.6% of the first degree relatives of the patients also had cholelithiasis and this trend was also in assertion as proved by another study [@bib29]. This point leads to contemplate a strong reason to screen the first degree relatives for gallstones.

Out of all 90.73% our participants were multipara. Parity has been accounted as one of the significant factors for GS(14). Sarin et al. [@bib30] mentioned about 94% of patients were multiparous in his study outcome.

A previous study made the fact apparent that the obese patients with an Asian lineage had raised diastolic blood pressure. Our study out came in the same harmony, as diasystolic BP was greater than 85 in 56.69%. Moreover the Systolic BP was also greater than 130 in 55.30%. Reason being people with hypertension may have more sympathetic nerve activities that may probably decrease bowel movements [@bib31].

Patients with gallstones have associated NAFLD, with concurrent metabolic syndrome and these ailments share similar factors for example obesity, hypertriglyceridemia and diabetes mellitus [@bib8]. The patients with metabolic syndrome had a co morbid of hypertention and diabeties at a p-values of 0.001. and 0.00, respectively which were highly significant. The patient with NAFLD had hypertention and diabetes as a co morbid at a p-values of 0.89 and 0.336, respectively.

The existing association between cholilithiasis and metabolic syndrome has never been studied before 2005. Afterwards Mendez-Sanchez et al. [@bib32] presented the first report which showed a very strong association among the two entities. The author was so much fascinated my that association that leaded him to conclude **" .... gallstone disease may be a part of metabolic syndrome."**The established association was later on got confirmed by studies with a large sample sizes [@bib16], [@bib33]. Ata N et al. indicated prophylactic surgery in patients with metabolic syndrome for gallstones [@bib33]. In our study 28.4% had metabolic syndrome.

Metabolic syndrome has the prevalence of 25% in Europe [@bib34] and 10--19% in Asia [@bib35]. The contributing factors for metabolic syndrome include sedentary lifestyle, genetic predisposition Specific macronutrients, and higher intake of total energy. Pakistan has prevalence of 18%--46%. About 46%--75% diabetic patients suffers metabolic syndrome [@bib35].

I-Ching Lin et al. reported difference in the means of HDL-C, BMI, TG, systolic B.P, diastolic B.P, fasting blood glucose and age between gallstone and non gallstone groups [@bib36]. These facts are also evident by our results more in patients with metabolic syndrome ([Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}). The mean TG was high i.e 162.52 with standard deviation of ± 37.79 in patients with metabolic syndrome than with no metabolic syndrome at very high significant p-vale of 0.00. Similar differences were also seen in HDL among the two groups with a significant p value of 0.001([Table 4](#tbl4){ref-type="table"}).

Apart from gall stone development there is other various concerns with metabolic syndrome as some studies have reported its association with diabetes, cardiovascular disease chronic kidney disease and nonalcoholic fatty liver disease [@bib37], [@bib38]. So, metabolic syndrome hovers as a gigantic health issue globally.

Non alcoholic fatty liver disease (NAFLD) has the prevalence of 15%--20% [@bib1]. It stands among the most common chronic liver conditions and is becoming the center of concern in the world of medicine [@bib39]. During the recent years its occurrence has been shown rising because of dramatically increased rates in obesity, metabolic syndrome and diabetes [@bib1].

The prevalence of NAFLD among outpatients is well established and described in various studies [@bib1], [@bib39] while the proportion for hospitalized patients not known [@bib39]. Further more the association of NAFL with other gastrointestinal conditions has not been into talk [@bib39].

In our study NAFLD was present in 62.5%. Moreover patients with NAFLD had a deranged and raised SGPT and SGOT levels ([Table 5](#tbl5){ref-type="table"}, [Table 6](#tbl6){ref-type="table"}). The means were raised in NAFLD patients i.e 74.41 and 75.72 respectively as compared to the ones with no NAFLD. The P-values were significant i.e. 0.002 and 0.006 respectively. Our results are in accordance with another study with similar objective [@bib29]. However presence of normal ranges of liver enzymes does not exclude NAFLD as rectified by some other series [@bib19], [@bib40]. Mofrad et al. as reported a NAFLD spectrums with normal values of ALT in retrospective series. The result of one series showed about 10% of the gallstone patients at the time of diagnosis had NAFLD progressed to fibrosis which was biopsy proven.

NAFLD contributes as the commonest cause that leads to cirrhosis, portal hypertension and hepatic cancer [@bib5] and it has been estimated that approximately 22% of NAFLD progresses to cirrhosis [@bib5]. One of the study justified for performing liver biopsy for the detection of NAFLD during cholecystectomy and that series captured more NAFLD in patients who undergone biopsies than those with simple ultrasound findings and liver function tests [@bib19]. We would like to mention here that this case series was done according to PROCESS Guidelines [@bib41].

6. Conclusion {#sec7}
=============

Non alcoholic fatty liver was highly prevalent in our study subjects. Based on our study results we recommend health education and implementation of lifestyle modification when patients present with gall stone disease requiring cholecystectomy as many of them could have NAFLD which may eventually progress to cirrhosis. We also found association of metabolic syndrome with gallstones and NAFLD. A huge percentage of first degree relatives of gall stone patients had gallstones and this relation was more pronounced patients who had associated NAFLD. A huge percentage of first degree relatives of gall stone patients had gallstones and this relation was more pronounced patients who had associated NAFLD.

Strengths and limitations of this study {#sec1}
=======================================

The study helped to enlighten the possible link between gallstone disease, NAFLD and MS which are top-line discussion topics nowadays. Many pertinent evidences were discussed along with the possible theories behind as their explanations. Not only this, we also discussed how outcomes of the study can help in future interventions. We also discussed if we could control MS and NAFLD occurrences we can minimize gallstone disease and respective surgery. And this all can help in decreasing the morbidity, mortality of gallstone and the complications due to its surgery.
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###### 

Education status.

Table 1

                  Frequency   Percent
  --------------- ----------- ---------
  Illiterate      27          30.7
  School          39          44.3
  Undergraduate   20          22.7
  Graduate        2           2.3
  Total           88          100.0

###### 

Exercise habit of participants.

Table 2

                 Frequency   Percent   Valid Percent   Cumulative Percent
  -------------- ----------- --------- --------------- --------------------
  No             71          80.7      80.7            80.7
  Rarely         2           2.3       2.3             83.0
  Once A Week    2           2.3       2.3             85.2
  Twice A Week   2           2.3       2.3             87.5
  Yes, Often     11          12.5      12.5            100.0
  Total          88          100.0     100.0           

###### 

Analysis of presence of metabolic syndrome relation status with SGPT, SGOT, BILIRUBIN, FBS, TRIGLYCERIDE and HDL.

Table 3

                                      N     Mean       Std. Deviation   Std. Error   95% Confidence Interval for Mean   Minimum    Minimum             
  ----------------------------------- ----- ---------- ---------------- ------------ ---------------------------------- ---------- ---------- -------- --------
  SGPT                                Yes   25         86.9600          83.20931     16.64186                           52.6129    121.3071   7.00     333.00
  No                                  63    48.0952    43.48627         5.47875      37.1434                            59.0471    7.00       300.00   
  Total                               88    59.1364    59.73604         6.36788      46.4795                            71.7932    7.00       333.00   
  SGOT                                Yes   25         75.0400          88.94637     17.78927                           38.3247    111.7553   8.00     333.00
  No                                  63    55.5238    52.64484         6.63263      42.2654                            68.7822    8.00       300.00   
  Total                               88    61.0682    65.08382         6.93796      47.2782                            74.8581    8.00       333.00   
  Total BILIRUBIN                     Yes   25         1.9088           3.45250      0.69050                            0.4837     3.3339     0.25     15.70
  No                                  63    1.3695     3.29433          0.41505      0.5399                             2.1992     0.10       23.80    
  Total                               88    1.5227     3.32898          0.35487      0.8174                             2.2281     0.10       23.80    
  Fasting plasma glucose level(FBS)   Yes   25         108.5600         37.12937     7.42587                            93.2337    123.8863   75.00    200.00
  No                                  63    102.4286   17.19688         2.16660      98.0976                            106.7595   75.00      180.00   
  Total                               88    104.1705   24.47012         2.60852      98.9857                            109.3552   75.00      200.00   
  TRIGLYCERIDE level                  Yes   25         162.5200         37.79453     7.55891                            146.9192   178.1208   81.00    215.00
  No                                  63    115.6190   45.58028         5.74258      104.1398                           127.0983   51.00      210.00   
  Total                               88    128.9432   48.24038         5.14244      118.7220                           139.1643   51.00      215.00   
  SERUM HDL                           Yes   25         98.3600          26.59085     5.31817                            87.3838    109.3362   32.00    150.00
  No                                  63    121.5556   27.50354         3.46512      114.6289                           128.4822   50.00      175.00   
  Total                               88    114.9659   29.06570         3.09841      108.8075                           121.1243   32.00      175.00   

###### 

Anova for metabolic syndrome status with SGPT,SGOT,BILIRUBIN,FBS,TRIGLYCERIDE and HDL.

Table 4

  ANOVA                                                                                                     
  ------------------------------ ---------------- ------------ ----------- ----------- ----------- -------- -------
  SGPT                           Between Groups   (Combined)   27033.975   1           27033.975   8.203    0.005
  Linear Term                    Unweighted       27033.975    1           27033.975   8.203       0.005    
  Weighted                       27033.975        1            27033.975   8.203       0.005                
  Within Groups                  283416.389       86           3295.539                                     
  Total                          310450.364       87                                                        
  SGOT                           Between Groups   (Combined)   6816.917    1           6816.917    1.621    0.206
  Linear Term                    Unweighted       6816.917     1           6816.917    1.621       0.206    
  Weighted                       6816.917         1            6816.917    1.621       0.206                
  Within Groups                  361706.674       86           4205.892                                     
  Total                          368523.591       87                                                        
  Total BILIRUBIN                Between Groups   (Combined)   5.205       1           5.205       0.467    0.496
  Linear Term                    Unweighted       5.205        1           5.205       0.467       0.496    
  Weighted                       5.205            1            5.205       0.467       0.496                
  Within Groups                  958.937          86           11.150                                       
  Total                          964.142          87                                                        
  Fasting plasma glucose level   Between Groups   (Combined)   672.855     1           672.855     1.125    0.292
  Linear Term                    Unweighted       672.855      1           672.855     1.125       0.292    
  Weighted                       672.855          1            672.855     1.125       0.292                
  Within Groups                  51421.589        86           597.925                                      
  Total                          52094.443        87                                                        
  TRIGLYCERIDE level             Between Groups   (Combined)   39369.619   1           39369.619   20.760   0.000
  Linear Term                    Unweighted       39369.619    1           39369.619   20.760      0.000    
  Weighted                       39369.619        1            39369.619   20.760      0.000                
  Within Groups                  163091.097       86           1896.408                                     
  Total                          202460.716       87                                                        
  Serum HDL                      Between Groups   (Combined)   9629.582    1           9629.582    12.966   0.001
  Linear Term                    Unweighted       9629.582     1           9629.582    12.966      0.001    
  Weighted                       9629.582         1            9629.582    12.966      0.001                
  Within Groups                  63869.316        86           742.666                                      
  Total                          73498.898        87                                                        

###### 

Analysis of presence OF NON alcoholic fatty liver disease status relation with SGPT,SGOT,BILIRUBIN,FBS,TRIGLYCERIDE and HDL.

Table 5

                                      N     Mean       Std. Deviation   Std. Error   95% Confidence Interval for Mean   Minimum    Maximum             
  ----------------------------------- ----- ---------- ---------------- ------------ ---------------------------------- ---------- ---------- -------- --------
  SGPT                                Yes   55         74.4182          66.67602     8.99059                            56.3931    92.4432    12.00    333.00
  No                                  33    33.6667    33.60215         5.84938      21.7519                            45.5815    7.00       200.00   
  Total                               88    59.1364    59.73604         6.36788      46.4795                            71.7932    7.00       333.00   
  SGOT                                Yes   55         75.7273          75.44865     10.17349                           55.3306    96.1239    9.00     333.00
  No                                  33    36.6364    30.41979         5.29541      25.8500                            47.4228    8.00       144.00   
  Total                               88    61.0682    65.08382         6.93796      47.2782                            74.8581    8.00       333.00   
  Total BILIRUBIN                     Yes   55         1.7747           3.87796      0.52290                            0.7264     2.8231     0.20     23.80
  No                                  33    1.1027     2.11207          0.36766      0.3538                             1.8516     0.10       12.43    
  Total                               88    1.5227     3.32898          0.35487      0.8174                             2.2281     0.10       23.80    
  Fasting plasma glucose level(FBS)   Yes   55         107.6545         28.66164     3.86473                            99.9062    115.4029   75.00    200.00
  No                                  33    98.3636    13.64006         2.37443      93.5271                            103.2002   75.00      130.00   
  Total                               88    104.1705   24.47012         2.60852      98.9857                            109.3552   75.00      200.00   
  TRIGLYCERIDE level                  Yes   55         130.5455         44.92785     6.05807                            118.3998   142.6912   51.00    215.00
  No                                  33    126.2727   53.93415         9.38873      107.1485                           145.3969   51.00      210.00   
  Total                               88    128.9432   48.24038         5.14244      118.7220                           139.1643   51.00      215.00   
  Serum HDL                           Yes   55         113.2727         30.01818     4.04765                            105.1577   121.3878   32.00    175.00
  No                                  33    117.7879   27.62444         4.80880      107.9927                           127.5831   50.00      160.00   
  Total                               88    114.9659   29.06570         3.09841      108.8075                           121.1243   32.00      175.00   

###### 

Anova for NON alcoholic fatty liver disease status WITH,SGOT,BILIRUBIN,FBS,TRIGLYCERIDE HDL.

Table 6

  ANOVA                                                                                                     
  ------------------------------ ---------------- ------------ ----------- ----------- ----------- -------- -------
  SGPT                           Between Groups   (Combined)   34251.648   1           34251.648   10.665   0.002
  Linear Term                    Unweighted       34251.648    1           34251.648   10.665      0.002    
  Weighted                       34251.648        1            34251.648   10.665      0.002                
  Within Groups                  276198.715       86           3211.613                                     
  Total                          310450.364       87                                                        
  SGOT                           Between Groups   (Combined)   31517.045   1           31517.045   8.043    0.006
  Linear Term                    Unweighted       31517.045    1           31517.045   8.043       0.006    
  Weighted                       31517.045        1            31517.045   8.043       0.006                
  Within Groups                  337006.545       86           3918.681                                     
  Total                          368523.591       87                                                        
  Total BILIRUBIN                Between Groups   (Combined)   9.314       1           9.314       0.839    0.362
  Linear Term                    Unweighted       9.314        1           9.314       0.839       0.362    
  Weighted                       9.314            1            9.314       0.839       0.362                
  Within Groups                  954.828          86           11.103                                       
  Total                          964.142          87                                                        
  Fasting plasma glucose level   Between Groups   (Combined)   1780.370    1           1780.370    3.043    0.085
  Linear Term                    Unweighted       1780.370     1           1780.370    3.043       0.085    
  Weighted                       1780.370         1            1780.370    3.043       0.085                
  Within Groups                  50314.073        86           585.047                                      
  Total                          52094.443        87                                                        
  TRIGLYCERIDE level             Between Groups   (Combined)   376.534     1           376.534     0.160    0.690
  Linear Term                    Unweighted       376.534      1           376.534     0.160       0.690    
  Weighted                       376.534          1            376.534     0.160       0.690                
  Within Groups                  202084.182       86           2349.816                                     
  Total                          202460.716       87                                                        
  Serum HDL                      Between Groups   (Combined)   420.473     1           420.473     0.495    0.484
  Linear Term                    Unweighted       420.473      1           420.473     0.495       0.484    
  Weighted                       420.473          1            420.473     0.495       0.484                
  Within Groups                  73078.424        86           849.749                                      
  Total                          73498.898        87                                                        
